CervoMed, Inc. (CRVO)
1.39
-0.06
(-4.14%)
USD |
NASDAQ |
Nov 06, 10:28
CervoMed Enterprise Value : -5.325M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | -5.325M |
| November 04, 2026 | -3.837M |
| November 03, 2026 | -3.973M |
| November 02, 2026 | -2.755M |
| October 30, 2026 | -3.296M |
| October 29, 2026 | -1.267M |
| October 28, 2026 | 4.955M |
| October 27, 2026 | 5.09M |
| October 26, 2026 | 5.360M |
| October 23, 2026 | 6.307M |
| October 22, 2026 | 5.360M |
| October 21, 2026 | 6.713M |
| October 20, 2026 | 6.037M |
| October 19, 2026 | 6.307M |
| October 16, 2026 | 5.360M |
| October 15, 2026 | 5.496M |
| October 14, 2026 | 6.037M |
| October 13, 2026 | 5.766M |
| October 12, 2026 | 9.013M |
| October 09, 2026 | 18.62M |
| October 08, 2026 | 19.43M |
| October 07, 2026 | 18.08M |
| October 06, 2026 | 20.24M |
| October 05, 2026 | 19.83M |
| October 02, 2026 | 15.91M |
| Date | Value |
|---|---|
| October 01, 2026 | 14.69M |
| September 30, 2026 | 15.23M |
| September 29, 2026 | 14.02M |
| September 28, 2026 | 11.18M |
| September 25, 2026 | 9.418M |
| September 24, 2026 | 9.148M |
| September 23, 2026 | 9.013M |
| September 22, 2026 | 9.283M |
| September 21, 2026 | 7.660M |
| September 18, 2026 | 7.930M |
| September 17, 2026 | 9.554M |
| September 16, 2026 | 8.066M |
| September 15, 2026 | 8.201M |
| September 14, 2026 | 9.283M |
| September 11, 2026 | 9.824M |
| September 10, 2026 | 8.607M |
| September 09, 2026 | 9.013M |
| September 08, 2026 | 9.283M |
| September 04, 2026 | 9.689M |
| September 03, 2026 | 9.418M |
| September 02, 2026 | 10.77M |
| September 01, 2026 | 9.824M |
| August 31, 2026 | 10.64M |
| August 28, 2026 | 10.23M |
| August 27, 2026 | 10.77M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.737B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Anika Therapeutics, Inc. | 245.53M |
| Savara, Inc. | 757.02M |
| Vericel Corp. | 2.582B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.572M |
| Total Expenses (Quarterly) | 6.572M |
| EPS Diluted (Quarterly) | -0.6415 |
| Earnings Yield | -231.0% |
| Normalized Earnings Yield | -230.99 |